Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 6/20 | 0.45 |
| ▸ | CD74 | P04233 | 4/20 | 0.43 |
| ▸ | CBX7 | O95931 | 3/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674408 | 0.89 | LMNA (0.45) | MAPTLMNAALDH1A1MIFCD74 | |
| SCHEMBL32674406 | 0.87 | LMNA (0.45) | MAPTLMNAALDH1A1MIFCD74 | |
| SCHEMBL32674387 | 0.87 | LMNA (0.45) | MAPTLMNAALDH1A1MIFCD74 | |
| SCHEMBL32674510 | 0.79 | MAPT (0.41) | MAPTLMNAALDH1A1MIFCD74 | |
| SCHEMBL32674496 | 0.74 | KMT2A (0.44) | LMNAALDH1A1MIFCD74TP53 | |
| SCHEMBL32674374 | 0.74 | KMO (0.45) | MAPTLMNAALDH1A1MIFCD74 | |
| SCHEMBL32674120 | 0.73 | MIF (0.41) | LMNAALDH1A1MIFCD74CBX7 | |
| SCHEMBL32674486 | 0.72 | ALDH1A1 (0.41) | MAPTALDH1A1MIFCD74 | |
| SCHEMBL238087 | 0.69 | APLNR (0.63) | MAPTALDH1A1APLNR | |
| SCHEMBL10089276 | 0.65 | MIF (0.78) | LMNAALDH1A1MIFCD74CBX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | ALK, NTRK1, NTRK3 | MAPT 43/4885LMNA 1027/4885ALDH1A1 2403/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | MAPT 380/4885LMNA 1664/4885ALDH1A1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.